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article under the CC BY-NC-ND licenseAbstract This study aimed to evaluate the anti-osteoporosis effect of CSN1S2 protein from
goat milk and yoghurt on a complete Freund’s adjuvant (CFA)-induced rheumatoid arthritis
(RA) model in rats. Twenty-four rats were randomly divided into six groups: control (untreated)
group (C), group treated with CSN1S2 (CM) protein from goat milk, group treated with CSN1S2
protein from goat yoghurt (CY), RA group, RA group treated with CSN1S2 protein from goat milk
(RAM), and RA group treated with goat yoghurt (RAY). Mineral elements and mesostructure
were analyzed using X-ray fluorescence and scanning electron microscopy. Bone histomorpho-
metry was analyzed using the BoneJ software. One way analysis of variance and Tukey post hoc
tests were used to analyze and compare the means of all variables between groups. The phos-
phorus levels were not significantly different between treatment groups relative to the control
group (p > 0.05), but were significantly higher in the CM and RAY groups relative to that
observed in the CY group (p < 0.05). CSN1S2 protein of goat milk repaired the collagen struc-
ture in the femur trabecular bone. The trabecular thickness and volume were significantly
lower in CM and CY groups relative to the control group (p < 0.05). The trabecular volume also
decreased significantly in the CM group relative to the control group (p < 0.05). The trabecular
thickness was significantly lower in the CY group relative to the CM group (p < 0.05), but theroup of Smart Molecule of Natural Genetics Resources, Department of Biology, Faculty of Sciences,
ng, East Java 65145, Indonesia.
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140 F. Fatchiyah et al.trabecular separation and trabecular volume were significantly greater (p < 0.05). The trabec-
ular volumes were significantly elevated in the RAM and RAY groups relative to the CM group
(p < 0.05). The trabecular thickness was significantly higher in the RAY group relative to the
CM and CY groups (p < 0.05). CSN1S2 protein of goat milk is better than goat yoghurt in repair-
ing femur crystallization and mesostructure in CFA-induced rheumatoid arthritis in rats.
Copyright ª 2016, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rheumatoid arthritis (RhA) is a chronic inflammatory dis-
ease with multiple risk factors. The pathomechanism of
RhA is associated with chronic soft-tissue inflammation
often followed by bone and cartilage destruction.1 Bone
complications are the major extra-articular complications
of RhA and can be described as three different forms:
periarticular bone loss, adjacent to the inflamed and
swelling joints; bone erosions, which share common
mechanisms with the periarticular osteopenia; and sys-
temic osteoporosis.2 Studies indicated that there is higher
frequency of osteoporosis and reduced bone mass in RhA
patients, in which the largest effect is found on the hip, as
compared to healthy controls.3e6 There is also a two-fold
increase in osteoporosis in female RhA patients ranging in
age from 20 years to 70 years,7 with osteoporosis being one
of the determinants of fracture risk. RhA patients have an
increased risk of fractures of the hip, vertebrae, and
pelvis.7e9 Studies also suggested that women with early-
onset RhA have significantly lower femoral neck and
whole-body bone-mineral density (BMD), but have similar
lumbar spine BMD as compared with controls. The fre-
quency of bone loss at all sites is significantly greater in
women with RhA than that of the controls.10
Nutritional disorders affect the pathological condition
and long-term outcome of physical functions in RhA. Many
studies have reported that malnutrition is a well-
recognized symptom associated with RhA.11 The values of
nutritional markers, such as albumin, are low in patients
with RhA, owing to malnutrition and excessive protein
catabolism triggered by high levels of inflammatory sub-
stances.12 Therefore, the nutritional status may be deeply
involved in RhA outcome or symptoms.
Bioactive peptides from milk proteins were included
within the primary sequence of native proteins that are
hydrolyzed by digestive enzymes and then cleaved and
modified to produce an active product as a fragment of
specific proteins. Bioactive peptides play important roles as
signaling molecules in physiological functions and
pathogenesis-related chronic diseases, such as hyperten-
sion, diabetes, cancer, and osteoporosis, as well as immu-
nomodulatory, anti-hypertension,13,14 anti-inflammation,15
anti-oxidative,16 and anti-glycosylation17 molecules. Milk
proteins are major suppliers of amino acids and micro-
nutrients in young mammals or humans. Milk is also rich in
biologically active peptides necessary for health. Bioactive
peptides are products of enzymatic fermentation that is an
important aspect of dietary proteins and offer adequatenutritional effects. Many researchers have reported that
peptide-derived milk fermentation products, such as
yogurt, cheese, or other fermented-foods, display more
beneficial biological functions related to cell signaling
pathways as compared to peptides from fresh
milk.13,14,18,19 However, the bioactive peptides from fresh
milk and yogurt that regulate pathways associated with
osteoporosis and RhA remain unclear.
Food-derived bioactive peptides represent a source of
health enhancing components that may be incorporated
into functional foods and/or used as nutraceuticals.20
Moreover, milk protein-derived bioactive peptides are
health-enhancing components that can be used to reduce
the risk of disease or to enhance certain physiological
functions.21 Whole casein and electrophoretic-casein frac-
tions have been shown to exhibit different biological ac-
tivities, such as immunomodulation.22,23 Our recent study
reported that goat milk has the alpha-S2 casein (CSN1S2), a
protein with a molecular weight of 36 kDa, which is not
present in bovine milk. We have also determined that this
protein contains eight peptides analyzed by matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry24; however, there is no study to evaluate the
ability of CSN1S2 protein isolated from goat milk and
yoghurt to inhibit femur osteoporosis in RhA. Therefore,
this study aimed to evaluate the anti-osteoporosis proper-
ties of CSN1S2 protein from goat milk or yoghurt in RhA-
associated osteoporosis.Materials and Methods
Animals
Twenty-four 12-week old adult male Wistar rats, weighing
150e200 g, were acclimatized for 1 week to the labora-
tory conditions prior to experimental manipulation. These
animals were purchased form Integrated Research and
Testing Laboratory, Gadjah Mada University, Yogyakarta,
Indonesia. The animals were exposed to a 12-hour light
and 12-hour dark cycle at room temperature of 24C. They
had free access to a standard laboratory diet and water ad
libitum. The animals were randomly divided into six
groups (n Z 4 each): control (untreated) group (C), group
receiving CSN1S2 protein from goat milk (CM), group
receiving CSN1S2 protein from goat yoghurt (CY), RhA
group (RA), RhA group receiving CSN1S2 from goat milk
(RAM), and RhA group receiving CSN1S2 from goat yoghurt
(RAY).
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The induction of arthritis in rats was performed according
to previous studies with modifications.19 Adjuvant-induced
arthritis in rats was established by a single subcutaneous
injection of 100 mL of complete Freund’s adjuvant (CFA,
SigmaeAldrich, St. Louis, MO, USA). Fourteen days after the
first injection, the rats were intradermally injected with
50 mL CFA in the lower extremity. Arthritic rats were
divided into RA, RAM, and RAY groups, while the rats that
did not receive CFA injections were divided into C, CM, and
CY groups.Preparation and administration of casein
The casein was isolated from milk samples from Etawah
goats (250 mL). The milk was heated to a temperature of
40C prior to addition of glacial acetic acid (5 mL) while
stirring until precipitate formation. The precipitate was
separated by filtration through a nylon mesh membrane.
The protein content was measured using a NanoDrop ma-
chine (NanoDrop; Thermo Scientific, Wilmington, DE, USA)
and then stored at 20C if not immediately used. The
CSN1S2 protein from goat milk and yoghurt was then orally
administrated to the rats by gavage at doses of 2 mL/kg
body weight according to a previous study with
modification.25Tissue preparation
At the end of the treatment, all rats were anesthetized
with diethyl ether. Both femurs were cut using a bone saw,
collected, weighed, and rinsed and cleaned with physio-
logical saline. All femur samples were stored in glutaral-
dehyde until analysis.Femoral bone mineral content
Femoral bone mineral content was analyzed by X-ray fluo-
rescence (XRF) by placing bones in a bone tube and scan-
ning according to manufacturer instructions. The bones
were analyzed at 20 kV accelerating voltage (MiniPAL 4;
PANalytical, Almelo, The Netherlands).26Femoral bone hydroxyapatite crystals
Characterization of the X-ray diffraction results was per-
formed using PANalytical X’Pert PRO-MPD (PANalytical B.V.,
Almelo, Netherlands). Subsequent analysis was performed
using the software programs as follows: High Score Plus
(PANalytical), Crystal Maker (CrystalMaker Software, Ltd.,
Begbroke, UK), and DDVIEW (http://www.icdd.com), com-
plemented with the latest version of PDF2 (http://www.
icdd.com). Diffraction spectra were recorded at an angle
of 2q, from 20 to 60, with a Cu-K a radiation source (wave
lengthZ 1.54056 A˚, 40 mA, 40 kV) and step size of 0.05.26
The lattice parameter of each mineral atomic coordinate
was visualized with crystal maker.Femur mesostructure
The femur head was cut with a scalpel. For scanning elec-
tron microscopy (SEM) evaluation, femurs from all groups
were cut vertically at the femoral head, and then the
femoral bones were fixed in phosphate-buffered formalin,
dehydrated in a graded concentration of ethanol, and
coated with gold and palladium. The processed bones were
then analyzed at 20 kV accelerating voltages by SEM
(Inspect TM S50; FEI, Hillsboro, OR, USA).26
Femur histomorphometry
Histomorphometric measurements were carried out ac-
cording to methods from a previous study with modifica-
tions.27 The measurements at the femur were performed at
500 objective magnification using a SEM (FEI), and then
the data were analyzed by an image analyzer BoneJ
(http://bonej.org/). The parameters measured in this
study were trabecular number, trabecular separation,
trabecular bone volume, and trabecular thickness.
Trabecular number (Tb.N, expressed per millimeter) and
trabecular separation (Tb.Sp, expressed per micrometer)
were calculated assuming that the trabecular bone could
be modeled by the parallel plates and bar model
(Tb.NZ Tb.Ar 10/Tb.Th; Tb.Sp Z 1000/Tb.N  Tb.Th).
Trabecular bone volume (BV/TV) is the amount of trabec-
ular bone within the spongy space (expressed as a per-
centage). Trabecular thickness (Tb.Th, expressed in
micrometers) was derived from trabecular perimeter
(B.Pm) and trabecular area (B.Ar) (Tb.Th Z 1.99 B.Ar/2/
B.Pm).28
Ethics
This study has been evaluated and approved by the
research ethics committee of Faculty of Sciences, Uni-
versitas Brawijaya, Malang, East Java, Indonesia (Registra-
tion number, KEP-90-UB).
Statistical analysis
Data are presented as mean  SD and differences between
groups were analyzed using one way analysis of variance
and the Tukey post hoc test with SPSS 16.0 statistical
package (SPSS, Inc., Chicago, IL, USA). A p value < 0.05 was
considered statistically significant.
Results
Mineral composition of CSN1S2 protein isolated
from goat milk and yoghurt
There were several inorganic compounds found in the
CSN1S2 protein from goat milk and yoghurt, including
phosphorus, sodium, calcium, iron, nickel, copper, and
ytterbium. The CSN1S2 protein from goat yoghurt had lower
levels of calcium and nickel, but higher levels of phos-
phorus as compared to the CSN1S2 protein from goat milk
(Table 1).
Table 1 Mineral content in the CSN1S2 protein from milk
and yoghurt.
Mineral contents (%) CSN1S2-milk CSN1S2-yoghurt
Phosphorus 5.1  0.3 4.6  0.1
Sodium 15.0  0.4 16.0  0.3
Calcium 39.0  0.8 52.4  0.5
Iron 6.6  0.07 7.0  0.1
Nickel 3.0  0.2 7.1  0.4
Copper 12.0  0.3 13.0  0.2
Ytterbium 19.0  1 0.0  0.0
Data are presented as mean  standard deviation.
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Table 2 presents the femoral bone mineral content for each
group. The levels of calcium, chromium, iron, copper, zinc,
nickel, and ytterbium were not significantly different be-
tween groups (p > 0.05). The phosphorus level in the CY
group was significantly lower as compared to the CM group
(p < 0.05). The phosphorus level was also significantly
higher in the RAY group relative to the CY group (p < 0.05).
Femoral bone hydroxyapatite crystal
Figure 1 shows the crystal size and lattice parameters. The
crystal size was increased in the RA group and all treated
groups as compared to the control (untreated) group. The
lattice parameters were different between groups. The
crystallinity was significantly higher in the CM, CY, RAM,
and RAY groups relative to the control (untreated) group
(p < 0.05). However, the crystallinity was not significantly
different in the RA group as compared to the control group
(p > 0.05). Inclusion of the CSN1S2 protein from goat milk
and yoghurt significantly increased the crystallinity relative
to the control (untreated) or RA groups (p < 0.05; Figure 2).
Femur mesostructure
The SEM results for the femur from the control (untreated)
group showed a step-ladder pattern of collagen withTable 2 Femoral-bone mineral content in treated and control
Mineral (%) C CM CY
Calcium 84.25  1.71 84.50  0.34 82.85  5.
Phosphorus 10.30  4.06 9.94  1.33 4.95  1.
Chromium 0.65  0.63 0.25  0.14 0.41  0.
Iron 0.98  0.10 0.85  0.39 1.65  0.
Nickel 1.05  1.74 0.95  0.76 2.32  2.
Copper 0.34  0.06 0.22  0.03 0.47  0.
Zinc 0.75  0.11 0.98  0.60 1.42  0.
Ytterbium 0.25  0.17 0.15  0.17 0.05  0.
Data are presented as mean  standard deviation.
CZ control (untreated) group; CFAZ complete Freund’s adjuvant; C
receiving CSN1S2 protein from goat yoghurt; RA Z RhA group; RAM Z
receiving CSN1S2 from goat yoghurt; RhA Z rheumatoid arthritis.
* p < 0.05 in comparison with CM group.
** p < 0.05 in comparison with CY group.granule formations covering the fibrillar collagen. In RA
rats, there were irregular step-ladder patterns of collagen
with resorption cavities and several hole sizes. The CSN1S2
protein from goat milk repaired the collagen structure in
trabecular bone, as indicated by the reduction in holes and
the rearrangement of fibrillar collagen into step-ladder
patterns (smooth surfaces). In groups administered CSN1S2
protein from goat yoghurt, the fibrillar collagen and irreg-
ular topography of the trabecular bone surface were still
observed (Figure 3).
Femur histomorphometry
Table 3 shows the characteristics of femoral trabecular
bone among treated supplementation and control groups.
The trabecular thickness and volume were significantly
lower in the CM and CY groups as compared to the control
group (p < 0.05). The trabecular volume was significantly
decreased in the CM group relative to the control group
(p < 0.05). All parameters were not significantly different
in the RA, RAM, and RAY groups as compared to the control
group (p > 0.05). The trabecular thickness was significantly
lower, but the other parameters were significantly larger in
the CY group relative to the CM group (p < 0.05). The
trabecular volume was significantly elevated in the RAM and
RAY groups relative to the CM group (p < 0.05). The
trabecular thickness was significantly higher in the RAY
group relative to the CM and CY groups (p < 0.05). How-
ever, all parameters were not significantly different in the
RAM or RAY groups as compared to the RA group (p < 0.05).
Discussion
The fermentation process may help improve nutritional
profiles. Foods produced through biotechnological pro-
cesses (such as fermentation) may prevent or at least
minimize the risk of lifestyle-related disease.29 Our findings
showed that the CSN1S2 protein from yoghurt (fermenta-
tion product) had lower levels of calcium and nickel, but
higher phosphorus as compared to the CSN1S2 protein from
goat milk. In the scope of bone health, although calcium is
one of the main minerals in bones, previous human studies(untreated) groups.
RA RAM RAY
83 81.60  3.11 82.95  0.17 83.65  3.05
21* 10.85  0.98 11.80  0.92 9.80  1.96**
09 0.66  0.61 0.57  0.48 0.58  0.37
63 1.26  0.98 1.16  0.62 1.15  0.39
16 1.54  0.39 1.66  0.83 2.41  0.39
05 0.48  0.31 0.43  0.21 0.47  0.09
77 0.75  0.51 0.56  0.30 0.67  0.27
05 0.15  0.17 0.35  0.40 0.50  0.57
MZ group receiving CSN1S2 protein from goat milk; CYZ group
RhA group receiving CSN1S2 from goat milk; RAY Z RhA group
Figure 1 Hydroxyapatite crystal and lattice parameters of femur from CFA-induced RhA in rats. The size of crystal was increased
in RhA groups with or without treatment and all control treatment group compared to control group. Blue circle, calcium; red
circle, oxygen; and brown circle, phosphorus. C Z control (untreated) group; CFA Z complete Freund’s adjuvant; CM Z group
receiving CSN1S2 protein from goat milk; CY Z group receiving CSN1S2 protein from goat yoghurt; RA Z RhA group; RAM Z RhA
group receiving CSN1S2 from goat milk; RAY Z RhA group receiving CSN1S2 from goat yoghurt; RhA Z rheumatoid arthritis.
a: x axis; b: y axis; c: z axis
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cium levels in hydroxyapatite crystal structures from oste-
oporosis patients.30,31 This phenomenon encouraged
investigation to discover the ideal mineral composition ofFigure 2 The percentage of femoral-bone crystallinity of
CFA-induced RhA in rats. Treatment with the CSN1S2 protein
from goat milk and increased crystallinity, which is significantly
different in the RhA group as compared to the control group.
C Z control (untreated) group; CFA Z complete Freund’s
adjuvant; CM Z group receiving CSN1S2 protein from goat
milk; CY Z group receiving CSN1S2 protein from goat yoghurt;
RAZ RhA group; RAMZ RhA group receiving CSN1S2 from goat
milk; RAY Z RhA group receiving CSN1S2 from goat yoghurt;
RhA Z rheumatoid arthritis. a: p < 0.05 in comparison with
control group; b: p < 0.05 in comparison with CM group; c: p <
0.05 in comparison with CY group; d: p < 0.05 in comparison
with RA group; e: p < 0.05 in comparison with RAM group.food aimed to inhibit osteoporosis and osteoporosis-related
disease.
The biological effects of inorganic compounds in pro-
cesses associated with bone formation and turnover have
also been described, leading to findings related to therapies
for bone disease and degradation. An example of such
therapy is the clinical use of strontium ranelate in patients
with osteoporosis.32 This study discovered several inorganic
compounds in the CSN1S2 protein from goat milk and
yoghurt, including phosphorus, sodium, calcium, iron,
nickel, copper, and ytterbium. Moreover, the CSN1S2 pro-
tein from goat yoghurt has higher levels of phosphorus and
lower levels of calcium and nickel relative to those
observed in the CSN1S2 protein from goat milk. These
minerals can be substituted or incorporated into hydroxy-
apatite crystals of the bone. Subsequently, the composition
of minerals in hydroxyapatite crystals determines bone
mesostructure and integrity.33 This study demonstrated
that the levels of calcium, chromium, iron, copper, zinc,
nickel, and ytterbium were not significantly different be-
tween groups (p > 0.05). This result may be due to the
substitution process that occurs when one of these minerals
replaces a comparable atom due to the similarities in their
radii and charges.34 This finding indicates that CFA-induced
RhA can cause osteoporosis, but possibly not as a result of
changes in mineral concentration. We hypothesized that
inflammation in RhA is a trigger of bone resorption. Our
previous data found that CFA-induced RhA inflammation
may not be interleukin-17 dependent, but rather depen-
dent upon the pro-inflammatory cytokine tumor necrosis
factor alpha (TNF-a), which could activate nuclear factor
kappa-B signaling involved in inflammation and apoptosis in
bone cells.35e37
Figure 3 Micrograph illustrating the mesostructure of rat femurs. In normal rats, step-ladder patterns of collagen (white arrow)
and granule formations (red arrow) covering the fibrillar collagen were observed. In RhA rats, there were irregular step-ladder
patterns of collagen (black arrow) combined with resorption cavities and various holes (yellow arrow). The CSN1S2 protein from
goat milk improved the collagen, as indicated by the reduction in holes and the arrangement of fibrillar collagen (step-ladder
patterns or smooth surfaces) in RhA rats. In groups administered the CSN1S2 protein from goat yoghurt, the fibrillar collagen and
irregular topography of the trabecular bone surface still existed in the RhA rats (SEM: 10.0 KV, magnification 2000). CZ control
(untreated) group; CFAZ complete Freund’s adjuvant; CMZ group receiving CSN1S2 protein from goat milk; CYZ group receiving
CSN1S2 protein from goat yoghurt; RAZ RhA group; RAMZ RhA group receiving CSN1S2 from goat milk; RAYZ RhA group receiving
CSN1S2 from goat yoghurt; RhA Z rheumatoid arthritis; SEM Z Scanning electron microscope.
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lower as compared to the CM group (p < 0.05). This finding
showed that the administration of yoghurt reduced the
femoral bone phosphorus level in normal rats. The phos-
phorus level was significantly higher in the RAY group
relative to that of the CY group (p < 0.05). The result
indicated that inflammatory conditions elevated the accu-
mulation of phosphorus absorbed from yoghurt, leading to
the increase in femoral bone mineral content. Additionally,
serum phosphorus levels also contributed to the femoral
phosphorous level. Previous studies postulated that the
elevation of phosphorus levels is related to tissue hypoxiaTable 3 The characteristics of femoral trabecular bone in trea
Indicator C CM CY
Tb.Th (mm) 3.42  1.03 2.00  0.26* 1.46  0.04*,**
Tb.Sp (mm) 1.26  0.47 0.84  0.00 1.24  0.20**
Tb.N (mm1) 897.04  331.97 1191.10  12.66 823.62  136.76*
BV/TV (%) 58.30  12.70 40.50  2.73* 50.80  2.97**
Data are presented as mean  standard deviation.
BV/TVZ trabecular volume; CZ control (untreated) group; CFAZ c
from goat milk; CYZ group receiving CSN1S2 protein from goat yoghu
milk; RAY Z RhA group receiving CSN1S2 from goat yoghurt;
Tb.Sp Z trabecular separation; Tb.N Z trabecular number.
* p < 0.05 in comparison with control group.
** p < 0.05 in comparison with CM group.
*** p < 0.05 in comparison with CY group.and an increase in ATP degradation, resulting in the release
of inorganic phosphorous from cells. Hypertrophy and hy-
perplasia creates a hypoxic environment in synovial
joints.38
The composition of mineral elements determines the
crystal size, crystal lattice parameters, and crystallinity.
This study demonstrated that the crystal size was increased
in the RA group and all treated groups compared to the
control group. The crystallinity was not significantly
different in the RA group as compared to the control group
(p > 0.05). This finding indicated that CFA-induced RhA did
not affect trabecular crystallinity. The treatment with theted and control (untreated) groups.
RA RAM RAY
1.90  1.35 1.92  0.72 3.09  0.58**,***
0.82  0.13*** 0.84  0.00*** 0.94  0.21
* 1250.40  207.13*** 1167.3  20.44*** 1104.90  247.18
48.85  11.55 48.70  5.80** 50.40  4.16**
omplete Freund’s adjuvant; CMZ group receiving CSN1S2 protein
rt; RAZ RhA group; RAMZ RhA group receiving CSN1S2 from goat
RhA Z rheumatoid arthritis; Tb.Th Z trabecular thickness;
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increased the crystallinity as compared with the control
(untreated) or RA groups (p < 0.05). Our findings indicated
that the CSN1S2 protein from goat milk and yoghurt
inhibited the amorphous states of crystals in normal or RhA
rats. The highest crystallinity was achieved by yoghurt
treatment, which was confirmed by hypergranulation
observed in the femur mesostructure. Osteoporosis is an
amorphous process caused by an irregular degenerative
condition, which is difficult to characterize in the scope of
wide ranges of bone mineralization.33 The growth of min-
erals in hydroxyapatite crystals occurs under specific ori-
entations, where the c-axis of the crystal is approximately
parallel to the length axis of the collagen fiber.39
Osteoporosis is characterized by a reduction in bone
mass and micro-architectural deterioration of the bone,
which increases bone fragility and fractures.40 Trabecular
bone strength is determined not only by the amount of
composite material (mineral, protein, and water), but also
the distribution of these materials (size, area, and struc-
tural properties). A number of properties, such as wall
thickness, well-connected trabeculae, and plate-like
trabeculae, confer better and stronger trabecular bone
properties.41e43 The trabecular region in the femur or tibia
may be the optimal region for detecting such bone loss.44
SEM of the femoral head of rats from the control (un-
treated) group showed step-ladder patterns of collagen
with granule formations covering the fibrillar collagen. In
RhA rats, there were irregular step-ladder patterns of
collagen with resorption cavities and several hole sizes, but
the levels of trabecular properties were not significantly
different in the RA group as compared to the control group
(p > 0.05). The CSN1S2 protein from goat milk repaired
collagen structure in trabecular bone, as indicated by the
reduction in holes and the rearrangement of fibrillar
collagen into step-ladder patterns (smooth surfaces). In
groups administered CSN1S2 protein from goat yoghurt, the
fibrillar collagen, irregular topography of trabecular bone
surface, and excessive granule formations remained.
Excessive granule formation indicated excessive bone for-
mation by osteoblasts. This may have been due to compo-
nents of yoghurt, such as lactoferrin, angiogenin, and
growth-factor binding proteins that contribute to the
mitogenic activity of osteoblasts.45,46
Based on histomorphometry analysis, the CSN1S2 protein
from goat milk was more effective than goat yoghurt in
maintaining trabecular thickness in normal rats. The
CSN1S2 protein from goat yoghurt increased trabecular
number and volume, but induced trabecular spacing. The
CSN1S2 protein from goat milk increased the trabecular
volume in RhA rats, but reduced the trabecular thickness.
Overall, this finding indicated that CFA-induced rheumatoid
arthritis in rats induced femur osteoporosis and rear-
rangement of the trabecular wall. The decrease in
trabecular thickness in the control group, but the increase
observed in the RAY group, indicated that yoghurt induced
trabecular bone turnover. The CSN1S2 protein from goat
milk is more effective than that from goat yoghurt in
repairing the crystallinity, collagen structure, and trabec-
ular mesostructure.
In conclusion our study suggested that CFA-induced RhA
in rats induced femoral bone osteoporosis. The CSN1S2protein from goat milk was more effective than goat
yoghurt at improving femoral bone crystallinity and meso-
structure in RhA rats. Therefore, the CSN1S2 protein from
goat milk is recommended as a source of bioactive peptides
for anti-osteoporosis effects in RhA.
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